Researchers examined how the associations of life event stress with impulsivity, anxiety, and depressed mood change in the presence of sleep disturbance.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.
The use of electrical stimulation devices to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration.
The group with persistent antisocial behavior also displayed reduced surface area in 282 of 360 anatomically defined parcels and thinner cortex in 11 of 360 parcels encompassing frontal and temporal regions related to executive function, emotion regulation, and motivation.
No difference was seen in the risk for serious neuropsychiatric events in patients who received oseltamivir in the 30 days after influenza diagnosis compared with those who did not.
Results showed a mean change from baseline of -9.28 points (95% CI, -10.23 to -8.32) on the HAM-A total score in patients treated with troriluzole compared with -9.35 points (95% CI, -10.34 to -8.36) with placebo (P =.917).
Depression, anxiety, and reduced quality of life are seen more frequently in patients with atopic eczema—and these associations imply that it may be more than just a skin disease.
In a Practice Guideline, recommendations are presented for the management of complex ADHD in childhood.
The results of the study point to the validity of the Research Domain Criteria initiative and suggest that neuroimaging findings may not be specific to certain psychiatric disorders.